Novo pulls plug on drug seen as key to its growth
In a major blow to growth prospects, Novo Nordisk As scuttled development of levermeloxifene, a ballyhooed drug in advanced testing against osteporosis. Levormeloxifene had been viewed as the crown
In a major blow to growth prospects, Novo Nordisk As scuttled development of levermeloxifene, a ballyhooed drug in advanced testing against osteporosis. Levormeloxifene had been viewed as the crown